Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, July 18th.
According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
A number of other analysts have also weighed in on the stock. Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, July 5th. Stifel Nicolaus upped their target price on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, April 3rd. Jefferies Group LLC set a $35.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 10th. Piper Jaffray Companies lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 target price on the stock. in a report on Monday, July 17th. Finally, BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $48.43.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at 42.10 on Tuesday. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of 21.25 and a beta of 1.31. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $44.95. The company’s 50 day moving average is $42.27 and its 200 day moving average is $33.33.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. Analysts anticipate that Supernus Pharmaceuticals will post $1.00 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Downgraded to “Hold” at Zacks Investment Research” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/08/zacks-investment-research-downgrades-supernus-pharmaceuticals-inc-nasdaqsupn-to-hold-updated-updated.html.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,735 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total value of $167,701.50. Following the completion of the transaction, the vice president now owns 21,209 shares of the company’s stock, valued at approximately $952,284.10. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total transaction of $114,764.40. Following the completion of the transaction, the vice president now directly owns 24,944 shares of the company’s stock, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. In the last three months, insiders sold 24,291 shares of company stock valued at $962,766. Corporate insiders own 6.70% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in SUPN. BlackRock Inc. boosted its position in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares in the last quarter. Vanguard Group Inc. boosted its position in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock worth $78,762,000 after buying an additional 156,094 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Supernus Pharmaceuticals by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock worth $52,236,000 after buying an additional 78,084 shares in the last quarter. Ranger Investment Management L.P. boosted its stake in shares of Supernus Pharmaceuticals by 2.8% in the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock worth $46,403,000 after buying an additional 40,131 shares during the period. Finally, Rice Hall James & Associates LLC boosted its stake in shares of Supernus Pharmaceuticals by 24.5% in the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after buying an additional 267,971 shares during the period. 94.39% of the stock is owned by institutional investors and hedge funds.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
